Blair Leavitt

Professor

The University of British Columbia
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Background Gene silencing is widely recognized as a promising therapeutic approach for dominant monogenic disorders. Current silencing strategies, many of which are transient, utilize RNA interference. Gene silencing may also be achieved through directed epigenetic editing using a CRISPR/dCas9 effector fused to DNA methyltransferase 3A (dCas9-DNMT3A). We used this system to direct DNA methylation to HTT , the causal gene underlying the autosomal dominant neurodegenerative disorder Huntington's disease, to assess the translational potential of this strategy for treating a genetic neurological disease. Objective To characterize the regulatory effect of targeted dCas9-DNMT3A-mediated DNA methylation at HTT . Methods We exploited DNA methylation profiles of high and low HTT -expressing tissues and targeted hypomethylated regions of HTT associated with high levels of HTT expression. Results De novo DNA methylation of loci within defined upstream, promoter, intragenic and downstream regions of HTT resulted in robust, acute silencing of HTT . The best long-term silencing of HTT , which persisted up to 30 days, was observed when targeted DNA methylation was directed to the 5’UTR and promoter regions of HTT . Conclusions HTT gene silencing may be achieved via targeted de novo DNA methylation within hypomethylated regulatory regions at the HTT locus. DNA methylation editing may be an attractive therapeutic approach for Huntington disease due to its potential for long-term silencing and reversibility.

Year:

2026

Microglia, the resident immune cells of the central nervous system, play a pivotal role in the response to Huntington's disease (HD) pathology. Through both cell-autonomous mechanisms and exposure to external pathogenic stimuli, microglia transition from a resting to an activated state, producing pro-inflammatory cytokines and chemokines that mediate inflammation. While this inflammatory response attempts to have a neuroprotective compensatory effect, chronic microglial activation exacerbates neuroinflammation, neurodegeneration and contributes to disease progression. Evidence from postmortem analyses and neuroimaging studies indicates that activated microglia are present in various stages of HD, correlating with neuronal degeneration and clinical symptoms. Enhanced microglial activation has been identified as an early predictor of disease onset, particularly in premanifest HD, highlighting the potential of targeting microglial pathways for therapeutic interventions. This review explores microglia's dual role in HD pathophysiology, exploring their contributions to both neuroinflammation and neuroprotection. It also examines recent advances in clinical trials aimed at modulating microglial activity, paving the way for novel therapeutic strategies to alter disease progression and improve patient outcomes.

Year:

2025

Year:

2025

Pyridoxine-dependent epilepsy (PDE) is a rare neurometabolic disorder of lysine catabolism caused by bi-allelic variants in ALDH7A1 . This enzyme deficiency leads to the accumulation of neurotoxic metabolites, pyridoxal-phosphate inactivation and consequently severe neurological symptoms. Current treatments, including vitamin B6 supplementation and lysine-restricted diets, partially alleviate seizures and intellectual disability but are not curative. To explore underlying mechanisms and potential therapies, we generated patient-derived human induced pluripotent stem lines (hiPSC) that were subsequently differentiated into astrocytes, the primary source of ALDH7A1 in the brain and key regulators of metabolic homeostasis. Metabolomic analyses confirmed elevated PDE biomarkers, and RNA sequencing revealed gene expression changes consistent with increased oxidative stress. Oxidative damage was validated by markers of DNA oxidation and lipid peroxidation. In addition, dysregulated oxygen consumption rates suggested mitochondrial dysfunction in PDE astrocytes. Notably, these pathological phenotypes were alleviated by downregulating AASS , the first enzyme of the lysine catabolism, by using CRISPR/Cas9 editing or antisense oligonucleotides (AON). This demonstrates that lysine catabolism underlies these phenotypes and highlights the therapeutic potential of AON therapy targeting AASS to reduce neurotoxic metabolite accumulation. These findings provide a promising strategy for developing targeted treatments for PDE and other rare neurometabolic disorders.

Year:

2025

Year:

2023

Year:

2023

Collaborators (11)

Marie Loh

Assistant Professor

Lee Kong Chian School of Medicine

SINGAPORE
View details

Dirk J. Lefeber

professor Glycosylation Disorders in Neurology

Radboud University Medical Center

NETHERLANDS
View details

Brian Christie

Professor

The University of British Columbia

CANADA
View details

Michael R. Hayden

Killam Professor

The University of British Columbia

CANADA
View details

Alex Garanto

Associate Professor / Research Group Leader

Radboudumc

NETHERLANDS
View details

Mahmoud Pouladi

The University of British Columbia

UNITED STATES
View details

Nicola Hobbs

Senior Research Fellow

University College London

UNITED KINGDOM
View details

Alexandra Durr

Professor, MD, PhD

Sorbonne Université

FRANCE
View details

Douglas Langbehn

Professor

Iowa State University

UNITED STATES
View details

Clara van Karnebeek

Professor

Radboud University Medical Center

NETHERLANDS
View details

Nael Nadif Kasri

Full professor

Radboudumc

NETHERLANDS
View details